Alembic Pharmaceuticals share price today

Alembic Pharmaceuticals Ltd's share price was ₹965.15 at the close on 6 November 2026. It has been stalling near its high for 3 weeks. That is 18.8% above its average price over the last 200 trading days. In the last 52 weeks it traded between ₹656 and ₹965, and at that close it was at the high of that range.

A share price tends to move through four phases: moving sideways (stage 1), rising (stage 2), stalling near a high (stage 3) and falling (stage 4). Today Alembic Pharmaceuticals Ltd is in stage 3. The phase helps read everything below.

Over the past 13 weeks it has done better than the NIFTY 500, and it has stayed ahead for 23 weeks in a row.

Over the last 11 years the share price moved +57% while the NIFTY 500 moved +251%, so it is behind the index over that whole period. The chart above shows the 13-week comparison for every week.

This page treats a rise as over when the price closes below its 200-day average on two Fridays in a row.

Two changes stood out: revenue up on a year earlier for 11 quarters in a row (every quarter we can compare) and highest quarterly revenue in 15 quarters.

1. Revenue up on a year earlier for 11 quarters in a row (every quarter we can compare)

   In the June 2026 quarter revenue was ₹2,150 crore, +25.7% on a year earlier.

2. Highest quarterly revenue in 15 quarters

   Revenue of ₹2,150 crore in the June 2026 quarter is the highest of the last 15 quarters.

For July to September 2026 (the quarter ended 30 September 2026), Alembic Pharmaceuticals reported revenue of ₹2,603 crore, up 36.3% from ₹1,910 crore a year earlier, and a profit of ₹334 crore, up 81.5% from ₹184 crore.

Alembic Pharmaceuticals results: July to September 2026 against a year earlier

The next results, for October to December 2026, are due by 14 February 2027: listed companies must publish quarterly results within 45 days of the quarter's end (60 days for the January to March quarter).

The newest call in our records is from 4 August 2026, about April to June 2026; a call about these results is not in our records yet.

From the company's reported quarterly results (quarter ended 30 September 2026). Revenue and profit in ₹ crore.

Alembic Pharmaceuticals closed at ₹965.15 on 6 November 2026, up 4.7% from ₹921.95 a year earlier (7 November 2025) and up 24.0% over five years. Its highest weekly close since March 2016 was ₹1,245.05 on 2 August 2024.

Alembic Pharmaceuticals share price: then and now

Weekly closing prices. Each change is the move from that price to the 6 Nov 2026 close. A day's intraday high or low can go beyond these weekly closes.

563 weekly closes from 11 March 2016 to 6 November 2026.

6 Nov 2026: Alembic Pharmaceuticals closed at ₹965.15, up 21.0% on the week and up 20.5% on the month. Results for July to September 2026: Revenue up 36.3% and profit up 81.5% on a year earlier.

Earlier

• 4 Aug 2026: Alembic Pharmaceuticals held its results call for April to June 2026.
• 29 Jul 2026: ex-date for a dividend of ₹12 a share.

Alembic Pharmaceuticals paid ₹12 a share in regular dividends in the 12 months to 7 November 2026 (1 payment), a yield of 1.24% at the ₹965.15 close on 6 November 2026. The last was a dividend of ₹12 a share, ex-date 29 July 2026.

Alembic Pharmaceuticals dividends since 1 April 2021

Amounts as the company declared them on the NSE. A dividend goes to whoever owns the shares before the ex-date.

Yes. Alembic Pharmaceuticals Ltd paid out 35% of its profit as dividends in FY26, and it paid a dividend in each of its last 13 reported years.

From the NSE corporate-actions record, read 7 November 2026.

On the call for April to June 2026, held on 4 August 2026, Alembic Pharmaceuticals' management spoke about the quarter; the main points are below.

Source: the call transcript.

From the call for April to June 2026, 4 August 2026. The July to September 2026 results are out since, so this part may be out of date until we update it.

Alembic Pharmaceuticals is on 2 of our India lists: Small & mid cap stocks and Pharma stocks.

Alembic Pharmaceuticals Ltd earned ₹334 Cr of net profit in the Sep 2026 quarter, +81.5% on the same quarter a year earlier. That is the 3rd quarter in a row of profit growth. Full-year FY26 profit was ₹671 Cr. Over 10 years profit has grown −0.7% a year on average. That is 12.8% of the quarter's revenue.

Net profit is what is left after every cost, interest and tax. Earnings per share, dividends and book value all grow from it.

The same quarter a year earlier earned ₹184 Cr.

For the full year, FY26 profit was ₹671 Cr (+15.3% on the year before).

Why profit moved: revenue changed +36.3% on a year earlier and the margin moved +5.0 percentage points. Most of the change came from keeping more of each sale.

On average over the last four quarters, profit changed +29.4% and revenue +19.3%. Profit is growing faster than sales: fixed costs are spread over more sales, so each extra rupee of revenue adds more to profit.

Alembic Pharmaceuticals Ltd reported ₹2,603 Cr of revenue in the Sep 2026 quarter, +36.3% on the same quarter a year earlier. That is the 12th quarter in a row with growth on the year before. Over 10 years it has grown 8.8% a year on average. The last full year, FY26, came in at ₹7,345 Cr.

Revenue is everything the company billed its customers in the period.

The last four reported quarters add to ₹8,477 Cr.

FY26 revenue was ₹7,345 Cr, +10.1% on the year before.

Recent pace: the last four quarters grew +19.3% on average, against 8.8% a year over the longer run, so this year is growing faster than its own long-run rate.

Is growth speeding up? Revenue over the last 12 months grew +19.7%, against +15.5% a year over the last 8 quarters (accelerating); profit over the last 12 months grew +32.7%, against +14.0% a year (accelerating).

Alembic Pharmaceuticals Ltd's operating margin was 22.0% in the Sep 2026 quarter, 5.0 percentage points higher than the same quarter a year ago. Across 13 years it has been between 12.0% and 32.0%. The latest quarter is within that range.

Operating margin is what is left from every ₹100 of sales after the costs of running the business, before interest and tax. It shows pricing power and cost control.

Why the margin moved: operating margin changed +5.0 percentage points on the year while gross margin changed +0.7 points. So the gain came mostly from costs below the gross margin, such as staff and overheads, measured against sales.

Over the last 3 years, 90% of Alembic Pharmaceuticals Ltd's reported profit came in as cash from its operations, so the profit is backed by cash. In FY26 it brought in ₹783 Cr of operating cash against ₹671 Cr of profit. After ₹722 Cr of spending on assets, ₹61.0 Cr was left over as free cash.

The profit and loss account shows what was earned. The cash-flow statement shows the cash that actually came in. Comparing operating cash flow with profit is one of the best checks that a profit is real.

Cash-flow figures here are yearly, because quarterly cash statements are not published, so this section changes once a year.

Why 90% of profit came in as cash: the cash cycle got 120 days longer between FY21 and FY26, so more of each rupee of profit waits in the business before it arrives.

What to look at next: the bigger use of cash is spending on new assets, at 1.9× depreciation over three years. The next section checks what that spending is building.

Alembic Pharmaceuticals Ltd's cash cycle, the days between paying suppliers and getting paid by customers, was 381 days in FY26, up from 261 days in FY21. It spent ₹1,636 Cr on assets over the last 3 years. Customers take 73 days to pay, and stock sits for 462 days on average.

Working capital is the cash tied up between paying suppliers and getting paid. Debtor days: how long customers take to pay. Inventory days: how long stock sits. The cash cycle: the whole loop, in days of sales.

At FY26 sales of ₹7,345 Cr, each day of that cycle ties up about ₹20.1 Cr, so roughly ₹7,667 Cr is tied up in the business at any time.

FY26: customers took 73 days to pay and stock sat for 462 days, about 15.2 months of sales sitting as stock, for a full cycle of 381 days, longer than FY21's 261.

The full loop: cash goes out to suppliers and production on day 0. Stock sits for 462 days. Customers pay about 73 days after that. Suppliers are paid at 154 days. Together that makes the 381-day cycle.

Spending on assets: ₹1,636 Cr over the last 3 years, against ₹871 Cr of depreciation (the yearly wear and tear on existing assets). So it is building well beyond replacing what wears out. Work still in progress is ₹683 Cr (FY26): assets paid for that are not earning yet.

In short: the cash is going into new capacity, not getting stuck in the daily cycle. The question is whether the new capacity earns.

Alembic Pharmaceuticals Ltd's P/E is 21.2×, in the middle of its own history: higher than 42% of past readings. Its usual P/E (the middle reading) is 23.3×, over 11 years of weekly prices. This compares the share price with the company’s own past. It does not say what the business is worth.

P/E is the share price divided by a year's profit per share: how many rupees the market pays for each rupee of yearly profit.

The P/E here, and its history, use a profit figure that can leave out one-off items, so it can differ from a P/E worked out on the quarterly results. Those results' earnings per share for the four quarters to Sep 2026 add up to ₹42.92.